Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy

被引：20

作者：

Al-Nawakil, Chadi ^{[1
,2
]}

Tamburini, Jerome ^{[2
]}

Bardet, Valerie ^{[2
,3
]}

Chapuis, Nicolas ^{[2
,3
]}

Bourry, Edward ^{[4
,5
]}

Roux, Christian ^{[2
,6
]}

Park, Sophie ^{[2
]}

Choquet, Sylvain ^{[4
,7
]}

Dreyfus, Francois ^{[2
]}

Bouscary, Didier ^{[2
]}

机构：

[1] Hop Cochin, AP HP, UF Hematol, Serv Med Interne, F-75014 Paris, France

[2] Univ Paris 05, Fac Med Rene Descartes, Paris, France

[3] Hop Cochin, Serv Hematol Biol, F-75014 Paris, France

[4] Univ Paris 06, Paris, France

[5] Hop La Pitie Salpetriere, Serv Nephrol, Paris, France

[6] Hop Cochin, Serv Rhumatol, F-75014 Paris, France

[7] Hop La Pitie Salpetriere, Serv Hematol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 10期

关键词：

D O I：

10.1080/10428190802290660

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2012 / 2014

页数：3

共 13 条

[11] PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma [J].

Oakervee, HE ;

Popat, R ;

Curry, N ;

Smith, P ;

Morris, C ;

Drake, M ;

Agrawal, S ;

Stec, J ;

Schenkein, D ;

Esseltine, DL ;

Cavenagh, JD .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) :755-762

[12] The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma [J].

Pellat-Deceunynck, C ;

Barillé, S ;

Jego, G ;

Puthier, D ;

Robillard, N ;

Pineau, D ;

Rapp, MJ ;

Harousseau, JL ;

Amiot, M ;

Bataille, R .

LEUKEMIA, 1998, 12 (12) :1977-1982

[13] Genetic aberrations and survival in plasma cell leukemia [J].

Tiedemann, R. E. ;

Gonzalez-Paz, N. ;

Kyle, R. A. ;

Santana-Davila, R. ;

Price-Troska, T. ;

Van Wier, S. A. ;

Chng, W. J. ;

Ketterling, R. P. ;

Gertz, M. A. ;

Henderson, K. ;

Greipp, P. R. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Rajkumar, S. V. ;

Bergsagel, P. L. ;

Stewart, A. K. ;

Fonseca, R. .

LEUKEMIA, 2008, 22 (05) :1044-1052

← 1 2 →